Role of Molecular-Genetic Profiling and Artificial Intelligence in Breast Cancer Diagnosis and insight into Targeted Pharmacotherapeutics
Keywords:
Social integration, responsibilities, relationships and mentorship, Metastasis., resistance, Genomics, sequencing, prosigna, transduction.Abstract
Breast cancer is a complex and diverse disease with varying responses to therapeutics. To address this diversity and offer personalized treatment plans, molecular and genetic analysis of breast tumors is crucial. The World Health Organization classifies breast cancer into different subtypes, including precursor lesions like Ductal carcinoma in-situ (DCIS), lobular carcinoma in-situ (LCIS), and Pleomorphic LCIS, which have the potential to develop into cancer. Invasive breast carcinomas infiltrate nearby tissues and can metastasize. These subtypes are categorized based on their microscopic appearances, such as Invasive Ductal Carcinoma (NOS), Invasive Lobular Carcinoma, Triple-Negative Breast Cancer (Estrogen receptor-, Progesterone receptor-, and, HER2-), HER2-Positive Breast Cancer (HER2 overexpression), and less common types like Mucinous, Metaplastic, and Papillary carcinomas. Molecular and genetic profiling are powerful tools to aid in treatment decisions. Understanding the underlying biology of the disease helps physicians develop personalized treatment plans that consider the unique characteristics of each patient’s tumor. Ongoing advancements in technology and research are improving our ability to diagnose and treat breast cancer effectively. This review presents an insight into molecular genetic profile, the role of artificial intelligence in breast cancer, and a concise overview of targeted pharmacotherapeutics for treating hormone receptor-based breast cancer.
References
M. I. Nounou, F. ElAmrawy, N. Ahmed, K. Abdelraouf, S. Goda, H. Syed-Sha-Qhattal (2015) Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies. 9(Suppl 2), 17-34. https://doi.org/10.4137/BCBCR.S29420
T. Yang, W. Li, T. Huang, J. Zhou (2023) Genetic Testing Enhances the Precision Diagnosis and Treatment of Breast Cancer. 24(23), 16607. https://doi.org/10.3390/ijms242316607
J. K. Litton, H. J. Burstein, N. C. Turner (2019) Molecular Testing in Breast Cancer. 39, e1-e7. https://doi.org/10.1200/EDBK_237715
J. Zhai, Y. Wu, F. Ma, V. Kaklamani, B. Xu (2023) Advances in Medical Treatment of Breast Cancer in 2022. 2(1), 1-17. https://doi.org/10.1002/cai2.46
S. Umakanthan, M. Bukelo, V. K. Chattu, et al (2021) Breast Cancer in Trinidad and Tobago: Etiopathogenesis, Histopathology and Receptor Study. 10(12), 4438-4445. https://doi.org/10.4103/jfmpc.jfmpc_627_21
H. Xu, B. Xu (2023) Breast Cancer: Epidemiology, Risk Factors and Screening. 35(6), 565-583. https://doi.org/10.21147/j.issn.1000-9604.2023.06.02
H. Fentie, P. A. M. Ntenda, F. N. Tiruneh (2023) Dietary Pattern and Other Factors of Breast Cancer among Women: A Case Control Study in Northwest Ethiopia. 23(1), 1050. https://doi.org/10.1186/s12885-023-11501-1
J. K. Jallah, T. J. Dweh, A. Anjankar, O. Palma (2023) A Review of the Advancements in Targeted Therapies for Breast Cancer. 15(10), e47847. https://doi.org/10.7759/cureus.47847
M. D. Mares-Quiñones, E. Galán-Vásquez, E. Pérez-Rueda, D. G. Pérez-Ishiwara, M. O. Medel-Flores, M. D. C. Gómez-García (2024) Identification of Modules and Key Genes Associated with Breast Cancer Subtypes through Network Analysis. 14(1), 12350. https://doi.org/10.1038/s41598-024-61908-4
A. Golestan, A. Tahmasebi, N. Maghsoodi, S. N. Faraji, C. Irajie, A. Ramezani (2024) Unveiling Promising Breast Cancer Biomarkers: An Integrative Approach Combining Bioinformatics Analysis and Experimental Verification. 24(1), 155. https://doi.org/10.1186/s12885-024-11913-7
K. Lin, S. Baritaki, S. Vivarelli, et al (2022) The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis. 11(6), 1195. https://doi.org/10.3390/antiox11061195
G. Lazzari, G. Buono, B. Zannino, G. Silvano (2021) Breast Cancer Adjuvant Radiotherapy in BRCA1/2, TP53, ATM Genes Mutations: Are There Solved Issues?. 13, 299-310. https://doi.org/10.2147/BCTT.S306075
A. A. Mohammed (2021) The Clinical Behavior of Different Molecular Subtypes of Breast Cancer. 29, 100469. https://doi.org/10.1016/j.ctarc.2021.100469
R. Munagala, F. Aqil, R. C. Gupta (2011) Promising Molecular Targeted Therapies in Breast Cancer. 43(3), 236-245. https://doi.org/10.4103/0253-7613.81497
L. Sun, A. Wu, G. R. Bean, I. S. Hagemann, C. Y. Lin (2021) Molecular Testing in Breast Cancer: Current Status and Future Directions. 23(11), 1422-1432. https://doi.org/10.1016/j.jmoldx.2021.07.026
M. Bou Zerdan, M. Ibrahim, C. E. Nakib, R. Hajjar, H. I. Assi (2021) Genomic Assays in Node Positive Breast Cancer Patients: A Review. 10. https://doi.org/10.3389/fonc.2020.609100
W. Audeh, L. Blumencranz, H. Kling, H. Trivedi, G. Srkalovic (2019) Prospective Validation of a Genomic Assay in Breast Cancer: The 70-gene MammaPrint Assay and the MINDACT Trial. 48(1), 18-34. https://doi.org/10.5644/ama2006-124.239
A. Ganguly, K. Leahy, A. M. Marshall, R. Dhulipala, L. Godmilow, T. Ganguly (1997) Genetic Testing for Breast Cancer Susceptibility: Frequency of BRCA1 and BRCA2 Mutations. 1(2), 85-90. https://doi.org/10.1089/gte.1997.1.85
D. Trapani, E. Crimini, J. Sandoval, G. Curigliano (2023) Next-Generation Sequencing for Advanced Breast Cancer: What the Way to Go?. 188, 343-351. https://doi.org/10.1007/978-3-031-33602-7_13
N. Pfarr, R. Penzel, V. Endris, et al (2017) Targeted Next-Generation Sequencing Enables Reliable Detection of HER2 (ERBB2) Status in Breast Cancer and Provides Ancillary Information of Clinical Relevance. 56(4), 255-265. https://doi.org/10.1002/gcc.22431
A. Arruabarrena-Aristorena, E. Toska (2022) Epigenetic Mechanisms Influencing Therapeutic Response in Breast Cancer. 12. https://doi.org/10.3389/fonc.2022.924808
J. Goldberg, N. Qiao, J. L. Guerriero, et al (2024) Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-Positive Breast Cancer. 4(2), 496-504. https://doi.org/10.1158/2767-9764.CRC-23-0244
F. B. De Abreu, G. N. Schwartz, W. A. Wells, G. J. Tsongalis (2014) Personalized Therapy for Breast Cancer. 86(1), 62-67. https://doi.org/10.1111/cge.12381
M. P. Lux, P. A. Fasching (2023) Breast Cancer and Genetic BRCA1/2 Testing in Routine Clinical Practice: Why, When and For Whom?. 83(3), 310-320. https://doi.org/10.1055/a-1929-2629
J. Fischgräbe, P. Wülfing (2008) Targeted Therapies in Breast Cancer: Established Drugs and Recent Developments. 3(2), 85-98. https://doi.org/10.2174/157488408784293732
N. Sarhangi, S. Hajjari, S. F. Heydari, M. Ganjizadeh, F. Rouhollah, M. Hasanzad (2022) Breast Cancer in the Era of Precision Medicine. 49(10), 10023-10037. https://doi.org/10.1007/s11033-022-07571-2
C. Le Tourneau, M. Kamal, A. M. Tsimberidou (2015) Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. 108(4), djv362. https://doi.org/10.1093/jnci/djv362
A. Gerger, U. Langsenlehner, W. Renner (2007) A Multigenic Approach to Predict Breast Cancer Risk. 104(2), 159-164. https://doi.org/10.1007/s10549-006-9408-4
F. M. Palmieri, E. A. Perez (2007) Managing High-Risk Breast Cancer. 23(1), 29-36. https://doi.org/10.1016/j.soncn.2006.11.005
T. Shien, H. Iwata (2020) Adjuvant and Neoadjuvant Therapy for Breast Cancer. 50(3), 225-229. https://doi.org/10.1093/jjco/hyz213
C. Thomssen, M. Vetter, E. J. Kantelhardt (2023) Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology Group. 15(5), 1580. https://doi.org/10.3390/cancers15051580
K. M. Turner, S. K. Yeo, T. M. Holm, E. Shaughnessy, J. L. Guan (2021) Heterogeneity within Molecular Subtypes of Breast Cancer. 321(2), C343-C354. https://doi.org/10.1152/ajpcell.00109.2021
M. Baliu-Piqué, A. Pandiella, A. Ocana (2020) Breast Cancer Heterogeneity and Response to Novel Therapeutics. 12(11), 3271. https://doi.org/10.3390/cancers12113271
R. Kern, S. C. Correa, T. B. Scandolara, J. C. da Silva, B. R. Pires, C. Panis (2020) Current Advances in the Diagnosis and Personalized Treatment of Breast Cancer: Lessons from Tumor Biology. 17(5), 399-420. https://doi.org/10.2217/pme-2020-0070
S. E. Tomlinson-Hansen, M. Khan, S. Cassaro (2023) Breast Ductal Carcinoma In Situ. https://www.statpearls.com/article/statpearls-breast-ductal-carcinoma-in-situ/
R. I. Udayasiri, T. Luo, K. L. Gorringe, S. B. Fox (2023) Identifying Recurrences and Metastasis after Ductal Carcinoma In Situ (DCIS) of the Breast. 82(1), 106-118. https://doi.org/10.1111/his.14804
C. Rutherford, R. Mercieca-Bebber, P. Butow, J. L. Wu, M. T. King (2017) Treatment Decision-Making in Ductal Carcinoma In Situ: A Mixed Methods Systematic Review of Women's Experiences and Information Needs. 100(9), 1654-1666. https://doi.org/10.1016/j.pec.2017.04.009
O. Loudig, M. I. Mitchell, I. Z. Ben-Dov, C. Liu, S. Fineberg (2022) MiRNA Expression Deregulation Correlates with the Oncotype DX® DCIS Score. 24(1), 62. https://doi.org/10.1186/s13058-022-01558-4
B. H. O. Chua (2024) Omission of Radiation Therapy Post Breast Conserving Surgery. 73, 103670. https://doi.org/10.1016/j.breast.2024.103670
F. Wärnberg, C. Wadsten, A. Karakatsanis, et al. (2023) Outcome of Different Radiotherapy Strategies after Breast Conserving Surgery in Patients with Ductal Carcinoma In Situ (DCIS). 62(9), 1045-1051. https://doi.org/10.1080/0284186X.2023.2245552
D. Ouattara, C. Mathelin, T. Özmen, M. Lodi (2023) Molecular Signatures in Ductal Carcinoma In Situ (DCIS): A Systematic Review and Meta-Analysis. 12(5), 2036. https://doi.org/10.3390/jcm12052036
E. Hahn, D. Rodin, R. Sutradhar, et al. (2023) Can Molecular Biomarkers Help Reduce the Overtreatment of DCIS?. 30(6), 5795-5806. https://doi.org/10.3390/curroncol30060433
M. A. Ameri, N. M. Shanbhag, A. Bin Sumaida, et al. (2024) Oncotype DX in Breast Cancer Management: Insights and Outcomes from the United Arab Emirates. 16(3), e56535. https://doi.org/10.7759/cureus.56535
C. Schagerholm, S. Robertson, H. Toosi, E. G. Sifakis, J. Hartman (2024) PIK3CA Mutations in Endocrine-Resistant Breast Cancer. 14(1), 12542. https://doi.org/10.1038/s41598-024-62664-1
D. Y. Chang, W. L. Ma, Y. S. Lu (2021) Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives. 17, 193-207. https://doi.org/10.2147/TCRM.S251668
P. Castel, E. Toska, J. A. Engelman, M. Scaltriti (2021) The Present and Future of PI3K Inhibitors for Cancer Therapy. 2(6), 587-597. https://doi.org/10.1038/s43018-021-00218-4
E. Robles-Rodriguez, L. Houser, B. Sanchez, et al (2024) Women's Knowledge of Genomic Testing and Precision Medicine in Breast Cancer Treatment Decision-Making. 51(3), 199-208. https://doi.org/10.1188/24.ONF.199-208
M. Zubair, S. Wang, N. Ali (2021) Advanced Approaches to Breast Cancer Classification and Diagnosis. 11. https://doi.org/10.3389/fphar.2020.632079
L. M. Guo, G. F. Ding, W. C. Xu, H. Ge, Y. Jiang, Y. F. Lu (2022) Anti-PD-L1 Antibody Enhances T Cell Immune Responses and Reduces Resistance of Breast Cancer Cells to Radiotherapy. 2022. https://doi.org/10.1155/2022/5938688
S. Cherri, E. Oneda, S. Noventa, L. Melocchi, A. Zaniboni (2022) Microsatellite Instability and Chemosensitivity in Solid Tumors. 14. https://doi.org/10.1177/17588359221099347
A. P. George, T. M. Kuzel, Y. Zhang, B. Zhang (2019) The Discovery of Biomarkers in Cancer Immunotherapy. 17, 484-497. https://doi.org/10.1016/j.csbj.2019.03.015
R. D. Chow, T. Michaels, S. Bellone, et al (2023) Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti-PD-1 Immunotherapy in Endometrial Carcinoma. 13(2), 312-331. https://doi.org/10.1158/2159-8290.CD-22-0686
M. Stibbards-Lyle, J. Malinovska, S. Badawy, P. Schedin, K. D. Rinker (2024) Status of Breast Cancer Detection in Young Women and Potential of Liquid Biopsy. 14. https://doi.org/10.3389/fonc.2024.1398196
J. Xu, H. Gao, X. Guan, et al (2024) Circulating Tumor DNA: From Discovery to Clinical Application in Breast Cancer. 15. https://doi.org/10.3389/fimmu.2024.1355887
E. Tzanikou, E. Lianidou (2020) The Potential of ctDNA Analysis in Breast Cancer. 57(1), 54-72. https://doi.org/10.1080/10408363.2019.1670615
Y. Y. Syed (2020) Oncotype DX Breast Recurrence Score®: A Review of Its Use in Early-Stage Breast Cancer. 24(5), 621-632. https://doi.org/10.1007/s40291-020-00482-7
Y. Malam, M. Rabie, K. Geropantas, S. Alexander, S. Pain, M. Youssef (2022) The Impact of Oncotype DX Testing on Adjuvant Chemotherapy Decision Making in 1-3 Node Positive Breast Cancer. 5(8), e1546. https://doi.org/10.1002/cnr2.1546
S. Tian, P. Roepman, L. J. Van't Veer, R. Bernards, F. de Snoo, A. M. Glas (2010) Biological Functions of the Genes in the Mammaprint Breast Cancer Profile Reflect the Hallmarks of Cancer. 5, 129-138. https://doi.org/10.4137/BMI.S6184
S. U. Baskota, D. J. Dabbs, B. Z. Clark, R. Bhargava (2021) Prosigna® Breast Cancer Assay: Histopathologic Correlation, Development, and Assessment of Size, Nodal Status, Ki-67 (SiNK™) Index for Breast Cancer Prognosis. 34(1), 70-76. https://doi.org/10.1038/s41379-020-0643-8
T. B. Sanft, J. Wong, B. O'Neal, et al. (2024) Impact of the Breast Cancer Index for Extended Endocrine Decision-Making: First Results of the Prospective BCI Registry Study. 22(2), 99-107. https://doi.org/10.6004/jnccn.2023.7087
T. M. Tilli (2021) Precision Medicine: Technological Impact into Breast Cancer Diagnosis, Treatment, and Decision Making. 11(12), 1348. https://doi.org/10.3390/jpm11121348
A. R. Katwaroo, V. S. Adesh, A. Lowtan, S. Umakanthan (2024) The Diagnostic, Therapeutic, and Ethical Impact of Artificial Intelligence in Modern Medicine. 100(1183), 289-296. https://doi.org/10.1093/postmj/qgad135
H. E. C. D. Silva, G. N. M. Santos, A. F. Leite, et al. (2023) The Use of Artificial Intelligence Tools in Cancer Detection Compared to the Traditional Diagnostic Imaging Methods: An Overview of the Systematic Reviews. 18(10), e0292063. https://doi.org/10.1371/journal.pone.0292063
A. Singh, S. B. Paruthy, V. Belsariya, et al. (2023) Revolutionizing Breast Healthcare: Harnessing the Role of Artificial Intelligence. 15(12), e50203. https://doi.org/10.7759/cureus.50203
O. Díaz, A. Rodríguez-Ruiz, I. Sechopoulos (2024) Artificial Intelligence for Breast Cancer Detection: Technology, Challenges, and Prospects. 175, 111457. https://doi.org/10.1016/j.ejrad.2024.111457
G. Gamsu, E. Perez (2003) Picture Archiving and Communication Systems (PACS). 18(3), 165-168. https://doi.org/10.1097/00005382-200307000-00005
J. M. Lee, L. E. Ichikawa, K. J. Wernli, et al (2021) Digital Mammography and Breast Tomosynthesis Performance in Women with a Personal History of Breast Cancer, 2007-2016. 300(2), 290-300. https://doi.org/10.1148/radiol.2021204581
S. Hussain, Y. Lafarga-Osuna, M. Ali, U. Naseem, M. Ahmed, J. G. Tamez-Peña (2023) Deep Learning, Radiomics, and Radiogenomics Applications in Digital Breast Tomosynthesis: A Systematic Review. 24(1), 401. https://doi.org/10.1186/s12859-023-05515-6
H. Chen, E. Cohen, D. Wilson, M. A. Alfred (2024) A Machine Learning Approach with Human-AI Collaboration for Automated Classification of Patient Safety Event Reports: Algorithm Development and Validation Study. 11, e53378. https://doi.org/10.2196/53378
A. M. Sebastian, D. Peter (2022) Artificial Intelligence in Cancer Research: Trends, Challenges, and Future Directions. 12(12), 1991. https://doi.org/10.3390/life12121991
Z. G. Jin, H. Zhang, M. H. Tai, Y. Yang, Y. Yao, Y. T. Guo (2023) Natural Language Processing in a Clinical Decision Support System for the Identification of Venous Thromboembolism: Algorithm Development and Validation. 25, e43153. https://doi.org/10.2196/43153
E. Hossain, R. Rana, N. Higgins, et al (2023) Natural Language Processing in Electronic Health Records in Relation to Healthcare Decision-Making: A Systematic Review. 155, 106649. https://doi.org/10.1016/j.compbiomed.2023.106649
C. W. Kim, J. M. Cha, M. S. Kwak (2021) Identification of Potential Biomarkers and Biological Pathways for Poor Clinical Outcome in Mucinous Colorectal Adenocarcinoma. 13(13), 3280. https://doi.org/10.3390/cancers13133280
V. Masoud, G. Pagès (2017) Targeted Therapies in Breast Cancer: New Challenges to Fight Against Resistance. 8(2), 120-134. https://doi.org/10.5306/wjco.v8.i2.120
M. Royce, T. Bachelot, C. Villanueva, et al (2018) Everolimus Plus Endocrine Therapy for Postmenopausal Women with Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial. 4(7), 977-984. https://doi.org/10.1001/jamaoncol.2018.0060
J. A. Beaver, B. H. Park (2012) The BOLERO-2 Trial: The Addition of Everolimus to Exemestane in the Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer. 8(6), 651-657. https://doi.org/10.2217/fon.12.49
W. Wu, J. Chen, H. Deng, et al (2021) Neoadjuvant Everolimus Plus Letrozole versus Fluorouracil, Epirubicin, and Cyclophosphamide for ER-Positive, HER2-Negative Breast Cancer: A Randomized Pilot Trial. 21(1), 862. https://doi.org/10.1186/s12885-021-08612-y
C. J. Curtaz, L. Kiesel, P. Meybohm, A. Wöckel, M. Burek (2022) Anti-Hormonal Therapy in Breast Cancer and Its Effect on the Blood-Brain Barrier. 14(20), 5132. https://doi.org/10.3390/cancers14205132
S. S. Park, J. I. Kim, C. H. Lee, et al (2022) Temsirolimus Enhances Anti-Cancer Immunity by Inducing Autophagy-Mediated Degradation of the Secretion of Small Extracellular Vesicle PD-L1. 14(17), 4081. https://doi.org/10.3390/cancers14174081
M. Park, D. Kim, S. Ko, A. Kim, K. Mo, H. Yoon (2022) Breast Cancer Metastasis: Mechanisms and Therapeutic Implications. 23(12), 6806. https://doi.org/10.3390/ijms23126806
D. Xu, W. Q. Chen, M. X. Liang, et al (2023) Tumor-Derived Small Extracellular Vesicles Promote Breast Cancer Progression by Upregulating PD-L1 Expression in Macrophages. 23(1), 137. https://doi.org/10.1186/s12935-023-02980-0
F. Mao, L. Gao, L. Liu, Y. Tang (2024) Enhanced Synergy of Pacritinib with Temsirolimus and Sunitinib in Preclinical Renal Cell Carcinoma Model by Targeting JAK2/STAT Pathway. 36(3), 238-248. https://doi.org/10.1080/1120009X.2023.2274700
F. Zagouri, T. N. Sergentanis, D. Chrysikos, M. Filipits, R. Bartsch (2012) mTOR Inhibitors in Breast Cancer: A Systematic Review. 127(3), 662-672. https://doi.org/10.1016/j.ygyno.2012.08.040
E. Zanardi, E. Verzoni, P. Grassi, et al (2015) Clinical Experience with Temsirolimus in the Treatment of Advanced Renal Cell Carcinoma. 7(3), 152-161. https://doi.org/10.1177/1756287215574457
D. Miricescu, A. Totan, I. I. Stanescu-Spinu, S. C. Badoiu, C. Stefani, M. Greabu (2020) PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects. 22(1), 173. https://doi.org/10.3390/ijms22010173
S. M. Schuetze, L. Zhao, R. Chugh, et al (2012) Results of a Phase II Study of Sirolimus and Cyclophosphamide in Patients with Advanced Sarcoma. 48(9), 1347-1353. https://doi.org/10.1016/j.ejca.2012.03.022
P. Fuso, M. Muratore, T. D'Angelo, et al (2022) PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives. 14(9), 2161. https://doi.org/10.3390/cancers14092161
A. Raphael, M. Salmon-Divon, J. Epstein, T. Zahavi, A. Sonnenblick, S. S. Shachar (2022) Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment. 13(10), 1763. https://doi.org/10.3390/genes13101763
F. André, E. Ciruelos, G. Rubovszky, et al (2019) Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. 380(20), 1929-1940. https://doi.org/10.1056/NEJMoa1813904
A. Dhakal, L. Acharya, R. O'Regan, S. Gandhi, C. Falkson (2021) PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer. 22(21), 11878. https://doi.org/10.3390/ijms222111878
S. Dent, J. Cortés, Y. H. Im, et al (2021) Phase III Randomized Study of Taselisib or Placebo with Fulvestrant in Estrogen Receptor-Positive, PIK3CA-Mutant, HER2-Negative, Advanced Breast Cancer: The SANDPIPER Trial. 32(2), 197-207. https://doi.org/10.1016/j.annonc.2020.10.596
M. N. Dickler, C. Saura, D. A. Richards, I. E. Krop, A. Cervantes, P. L. Bedard, M. R. Patel, L. Pusztai, M. Oliveira, A. K. Cardenas, N. Cui (2018) Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer. 24(18), 4380–4387. https://doi.org/10.1158/1078-0432.CCR-14-0947
A. Bertucci, F. Bertucci, A. Gonçalves (2023) Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements. 15(5), 1416. https://doi.org/10.3390/cancers15051416
D. Sarker, J. E. Ang, R. Baird, et al (2015) First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors. 21(1), 77-86. https://doi.org/10.1158/1078-0432.CCR-14-0947
P. Schmid, S. E. Pinder, D. Wheatley, et al (2016) Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared with Anastrozole Alone in Patients with Estrogen Receptor-Positive Breast Cancer. 34(17), 1987-1994. https://doi.org/10.1200/JCO.2015.63.9179
M. Scaltriti, C. Verma, M. Guzman, et al (2009) Lapatinib, a HER2 Tyrosine Kinase Inhibitor, Induces Stabilization and Accumulation of HER2 and Potentiates Trastuzumab-Dependent Cell Cytotoxicity. 28(6), 803.
A. Moreno-Aspitia, E. M. Holmes, C. Jackisch, et al (2021) Updated Results from the International Phase III ALTTO Trial (BIG 2-06/Alliance No63D). 148, 287-296. https://doi.org/10.1016/j.ejca.2021.01.053
A. Pellerino, R. Soffietti, F. Bruno, et al (2022) Neratinib and Capecitabine for the Treatment of Leptomeningeal Metastases from HER2-Positive Breast Cancer: A Series in the Setting of a Compassionate Program. 14(5), 1192. https://doi.org/10.3390/cancers14051192
D. Olson, J. Taylor, K. Willis, et al (2023) HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-Positive Breast Cancer. 3(9), 1927-1939. https://doi.org/10.1158/2767-9764.CRC-23-0302
Z. Sirhan, A. Thyagarajan, R. P. Sahu (2022) The Efficacy of Tucatinib-Based Therapeutic Approaches for HER2-Positive Breast Cancer. 9(1), 39. https://doi.org/10.1186/s40779-022-00401-3
A. Kulukian, J. Taylor, N. Jain, D. Olson, M. Zaval, R. Thurman, S. Hengel, L. Farr, T. Pires, S. R. Peterson (2021) Abstract PS10-08: Tucatinib Potentiates the Activity of the Antibody-Drug Conjugate T-DM1 in Preclinical Models of HER2-Positive Breast Cancer. 81(4_Supplement), PS10-08.
K. McKeage, C. M. Perry (2002) Trastuzumab: A Review of Its Use in the Treatment of Metastatic Breast Cancer Overexpressing HER2. 62(1), 209-243. https://doi.org/10.2165/00003495-200262010-00008
D. R. Spigel, H. J. Burstein (2002) HER2 Overexpressing Metastatic Breast Cancer. 3(2), 163-174. https://doi.org/10.1007/s11864-002-0062-8
J. Kreutzfeldt, B. Rozeboom, N. Dey, P. De (2020) The Trastuzumab Era: Current and Upcoming Targeted HER2+ Breast Cancer Therapies. 10(4), 1045-1067.
M. Robert, J. S. Frenel, E. Bourbouloux, et al (2020) Pertuzumab for the Treatment of Breast Cancer. 20(2), 85-95. https://doi.org/10.1080/14737140.2019.1596805
M. F. Mercogliano, S. Bruni, F. L. Mauro, R. Schillaci (2023) Emerging Targeted Therapies for HER2-Positive Breast Cancer. 15(7), 1987. https://doi.org/10.3390/cancers15071987
W. J. Gradishar, R. O'Regan, M. F. Rimawi, J. L. Nordstrom, M. K. Rosales, H. S. Rugo (2023) Margetuximab in HER2-Positive Metastatic Breast Cancer. 19(16), 1099-1112. https://doi.org/10.2217/fon-2022-1040
M. M. A. Alasmari (2022) A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer. 15(1), 38. https://doi.org/10.3390/cancers15010038
D. Feng, Y. Guan, M. Liu, et al. (2021) Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment with Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature. 12, 608292. https://doi.org/10.3389/fimmu.2021.608292
Y. Liu, Y. Hu, J. Xue, et al. (2023) Advances in Immunotherapy for Triple-Negative Breast Cancer. 22(1), 145. https://doi.org/10.1186/s12943-023-01850-7
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Authors and Global Journals Private Limited
This work is licensed under a Creative Commons Attribution 4.0 International License.
